Conditions: Metastatic Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 176
Healthy volunteers: no

Brief summary:
The purpose of this study was to determine the effects of the weekly regimen of ixabepilone dosing compared to the once every 3 week dosing regimen in participants with metastatic breast cancer.

Detailed description:

Arms:
arm 1: ixabepilone 16 mg/m\^2 weekly for 3 weeks followed by 1 week rest arm 2: ixabepilone 40 mg/m\^2 every 3 weeks

Interventions: intervention 1: Ixabepilone intervention 2: Ixabepilone
Intervention descriptions: intervention 1: Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m\^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity. intervention 2: Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.

Protocol document: